24.10.2014 • NewsActavisBloombergBoehringer Ingelheim

Boehringer Not Bidding for Belgian Drugmaker

Boehringer Ingelheim is not bidding for Belgian over-the-counter drugmaker Omega Pharma, a company spokesperson has confirmed.

News agencies reported earlier this week that the German company was among potential bidders, which were also said to include US generic producers Actavis, Ireland-based consumer health company Perrigo and French drugmaker Sanofi.

Final bids for the Belgian firm based at Nazareth are expected by the beginning of November. Omega is said likely to command an asking price of €4 billion.

In the first half of 2014, the company with a portfolio that includes toiletries, posted sales of just under €650 million and an operating profit of nearly €150 million.

The news agency Bloomberg had speculated that Boehringer could be interested in beefing up its OTC portfolio as patents on a number of prescription drugs are due to expire in the near future.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.